Allarity Therapeutics and Lonza to Develop and Manufacture Dovitinib

Allarity Therapeutics A/S, a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers, and Lonza, a CDMO partner to the biopharma industry, have signed an agreement to develop and manufacture dovitinib, a pan-tyrosine kinase inhibitor.